

More information on the trials listed below is available at PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at [www.cancer.gov/clinicaltrials](http://www.cancer.gov/clinicaltrials). A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.

## Phase III

**Study of Ifosfamide and Doxorubicin Hydrochloride, Radiotherapy, and/or Surgery in Patients With Localized Non-Rhabdomyosarcoma Soft Tissue Sarcoma**

NCT00334854

**Randomized Study of Doxorubicin With Versus Without Ifosfamide and Pegfilgrastim in Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma**

NCT00061984

**Randomized Study of Doxorubicin Hydrochloride, Cyclophosphamide, Vincristine, Etoposide, and Ifosfamide With Versus Without Topotecan Hydrochloride in Patients With Newly Diagnosed Localized Ewing's Sarcoma**

NCT00334867

**Randomized Study of Neoadjuvant Induction Therapy Comprising Doxorubicin, Cisplatin, and High-Dose Methotrexate (MAP) Followed by Surgery and Adjuvant Maintenance Therapy Comprising MAP Alone Versus MAP and PEG-Interferon Alfa-2b OR MAP Combined With Ifosfamide and Etoposide in Patients With Resectable High-Grade Osteosarcoma**

NCT00134030

**Randomized Study of Adjuvant Imatinib Mesylate Versus Observation Only in Patients With Completely Resected Localized Gastrointestinal Stromal Tumor at Intermediate- or High-Risk of Relapse**

NCT00103168

**Prospective Multicentric Randomized Study of Gleevec in Advanced Gastrointestinal Stromal Tumors Expressing c-Kit: Interruption After 3 Years vs Maintenance**

NCT00367861

**Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)**

NCT00116935

## Phase II

**Study of Bevacizumab in Patients With Classic or Epidemic Kaposi's Sarcoma**

NCT00058136

**Study of Imatinib Mesylate (Gleevec) in Patients With HIV-Related Kaposi's Sarcoma**

NCT00090987

**Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas**

NCT00356031

**Study of Sorafenib in Patients With Metastatic, Locally Advanced, or Locally Recurrent Non-Gastrointestinal Stromal Sarcoma**

NCT00245102

**Randomized Study of Vincristine, Topotecan Hydrochloride, and Cyclophosphamide With Versus Without Bevacizumab in Younger Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma**

NCT00516295

**Pilot Study of Induction Chemotherapy Followed by Allogeneic/Syngeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk, Recurrent Pediatric Sarcoma**

NCT00047372

**Study of External Beam Radiation With Intratumoral Injection of Dendritic Cells as Neoadjuvant Treatment for Sarcoma**

NCT00365872

**Study of Cytarabine in Younger Patients With Recurrent or Refractory Ewing's Sarcoma**

NCT00470275

**Study of Sunitinib Malate in Patients With Metastatic, Locally Advanced, or Locally Recurrent Non-Gastrointestinal Stromal Tumor Sarcomas**

NCT00474994

**Study of Locally Advanced/Metastatic Soft Tissue Sarcoma or Imatinib Mesylate Refractory Advanced/Metastatic Malignant GIST**

NCT00359333

**Study of IMRT Lower Limb Soft Tissue Sarcoma**

NCT00188175

**Study of Radiation Therapy to Treat Musculoskeletal Tumors**

NCT00186992

**Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma**  
NCT00400569

**Randomized Study of Gemcitabine With Versus Without Docetaxel as Second-Line Therapy in Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma**  
NCT00227669

**Study of Intensive Chemotherapy Comprising Vincristine, Dactinomycin, and Cyclophosphamide Followed by Vincristine and Dactinomycin in Patients With Lower-Risk Embryonal Rhabdomyosarcoma**  
NCT00245089

**Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumors or in Relapse**  
NCT00180947

**Study of Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes**  
NCT00171912

**Study of the Biological Activity of AZD2171 in GIST**  
NCT00385203

**Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans**  
NCT00176709

**Study of Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans**  
NCT00243191

**Study of Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma**  
NCT00441467

**Study of Adjuvant Imatinib in High-Risk GIST With c-Kit Mutation**  
NCT00278876

## Phase I/II

**Study of Sorafenib in Patients With Kaposi's Sarcoma**  
NCT00304122

**Study of ZIO-201 in Advanced Sarcoma**  
NCT00439686

**Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma**  
NCT00276055

**Study of Radiation Therapy as Palliative Treatment of GIST**  
NCT00515931

---

The following trials are currently being conducted at Moffitt Cancer Center. For additional information about these trials, please contact Hugh Shrager at (813) 745-5419 or e-mail: [hugh.shrager@moffitt.org](mailto:hugh.shrager@moffitt.org).

## Phase II

**Open-label Study of Sunitinib Malate (SU011248) in Adult Subjects With Metastatic and/ or Surgically Unresectable Soft Tissue Sarcoma**  
MCC14902

**Study of Perifosine in Patients with Chemo-Insensitive Sarcomas**  
MCC15029

**Study of LY573636-sodium Administered as Second-line or Third-line Treatment in Patients with Unresectable or Metastatic Soft Tissue Sarcoma**  
MCC15195